Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 641 - 660 ( 667 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued as Follow-on Compounds Could Launch Along Side Eteplirsen
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued as Follow-on Compounds Could Launch Along Side Eteplirsen; Updating Price Target Due To Financing - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of January 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Results - Awaiting Details of the End of Phase II
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expert Call Highlights - Eteplirsen''s "Impressive" Clinical Benefit "Very Promising"
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TODAY: Expert Conference Call with Dr. Craig M. McDonald, M.D. on Duchenne Muscular Dystrophy Disease Progression and Clinical Endpoints.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Results at World Muscle Society Provide Additional Support for Eteplirsen''s Efficacy
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen 48-Week Data Preview: Longer-Term Administration Key to Eteplirsen''s Clinical Benefit - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen Reportedly Improves Quality of Life of a DMD Patient
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen Reportedly Improves Quality of Life of a DMD Patient
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 Update - Eteplirsen Program Remains Attractive - Ebola Stop Work Order Non-Event - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports FY 2Q12 Earnings; Several Upcoming Catalysts in 2H12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports FY 2Q12 Earnings; Several Upcoming Catalysts in 2H12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M